Eli Lilly outlays $2.3bn to acquire blood cancer specialist Ajax Therapeutics Pharmaceutical Technology 20:13 Mon, 27 Apr
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera PR Newswire (Press Release) 11:48 Mon, 27 Apr